Seven Grand Managers LLC Invests $685,000 in Dyne Therapeutics, Inc. $DYN

Seven Grand Managers LLC bought a new position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 35,000 shares of the company’s stock, valued at approximately $685,000.

A number of other large investors also recently modified their holdings of DYN. Chung Wu Investment Group LLC acquired a new position in shares of Dyne Therapeutics during the third quarter worth approximately $30,000. Strs Ohio acquired a new position in shares of Dyne Therapeutics during the fourth quarter worth approximately $51,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Dyne Therapeutics by 25.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock worth $70,000 after purchasing an additional 1,109 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Dyne Therapeutics by 275.1% during the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock worth $100,000 after purchasing an additional 7,697 shares in the last quarter. Finally, Prudential Financial Inc. acquired a new position in shares of Dyne Therapeutics during the second quarter worth approximately $111,000. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Dyne Therapeutics Trading Up 0.1%

Shares of NASDAQ DYN opened at $18.16 on Thursday. The company’s 50 day simple moving average is $18.27 and its 200 day simple moving average is $18.31. Dyne Therapeutics, Inc. has a fifty-two week low of $8.06 and a fifty-two week high of $25.00. The firm has a market capitalization of $3.00 billion, a P/E ratio of -5.64 and a beta of 1.08. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same quarter last year, the business earned ($1.05) earnings per share. On average, analysts predict that Dyne Therapeutics, Inc. will post -2.99 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Jefferies Financial Group reiterated a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, March 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday, April 20th. Evercore set a $33.00 price objective on shares of Dyne Therapeutics in a report on Friday, May 15th. Sanford C. Bernstein increased their price objective on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a report on Wednesday, May 13th. Finally, Wall Street Zen upgraded shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Three analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $35.00.

Insider Buying and Selling

In other Dyne Therapeutics news, CFO Erick Lucera sold 1,448 shares of the stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $18.36, for a total value of $26,585.28. Following the sale, the chief financial officer directly owned 123,925 shares in the company, valued at approximately $2,275,263. This trade represents a 1.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Douglas Kerr sold 1,564 shares of the stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $18.36, for a total transaction of $28,715.04. Following the completion of the sale, the insider owned 170,042 shares in the company, valued at approximately $3,121,971.12. This trade represents a 0.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 1,559,462 shares of company stock valued at $29,814,746. 14.14% of the stock is owned by company insiders.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.